News and Announcements
OncoSil Appoints Independent Non-Executive Director
- Published January 21, 2016 10:19AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
21st January 2016, ASX Announcement
OncoSil Medical Limited (ASX: OSL) is pleased to announce the appointment today of Dr Chris Roberts as an Independent Non-Executive Director of the Company, with immediate effect.
Dr Robert is a highly experienced director and senior executive with 40 years’ experience in the medical innovation space. During this time he has served on the boards of a number of ASX listed companies as well as research institutions and government entities.
Dr Roberts has forged a long and successful career in the medical device sector. He was Chief Executive Officer/President of Cochlear Limited (ASX: COH) from February 2004 to August 2015. Cochlear is the global market leader in inplantable devices, such as cochlear implants, for the hearing impaired. Dr Roberts was primarily responsible for the significant increase in the Cochlear Limited’s sales from $348m in 2005 to $926m in 2015.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
